Vani J. Sabesan, MD, and colleagues categorized 80 patients undergoing arthroscopic rotator cuff repair into groups based on whether they received a local infiltration of 20 mg liposomal bupivacaine ...

September 19, 2024 — For older adults undergoing hemiarthroplasty for hip fracture, intraoperative use of liposomal bupivacaine does not improve pain scores or other relevant outcomes, compared to ...

Please provide your email address to receive an email when new articles are posted on . Use of liposomal bupivacaine in an interscalene nerve block effectively controlled pain after outpatient ...

Knee replacement is highly successful for treating severe arthritis. There are 100,000 people who undergo knee replacement surgery every year in the UK, with numbers set to rise significantly in ...

Background Multimodal analgesia following total hip arthroplasty has been shown to improve patient satisfaction, participation with physical therapy, and allow early return to self care. Liposomal ...

The researchers observed no significant differences between the groups for average postoperative pain score. HealthDay News — Liposomal bupivacaine is not associated with significant improvement in ...

Liposomal bupivacaine represents a significant advancement in postoperative pain management. By encapsulating bupivacaine in lipid vesicles, this formulation harnesses a biphasic release profile that ...

No clinically relevant reduction in inpatient opioid use, costs for patients undergoing total knee arthroplasty. HealthDay News — Liposomal bupivacaine use in patients undergoing total knee ...

Liposomal bupivacaine was launched on the market twelve years ago to provide long-lasting local control of pain. The medication is used as a local anesthetic, particularly for orthopedic operations. A ...

Liposomal bupivacaine is marketed as an alternative to reduce the need for postoperative opioids. 'Worth questioning' liposomal bupivacaine in geriatric hip fracture In both groups, time to ambulation ...

Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has announced data from a sciatic nerve preclinical study designed to evaluate Probudur, Virpax's liposomal bupivacaine product candidate. This study's ...

Liposomal bupivacaine is a formulation of local anesthetic approved by the FDA in October 2011 for single-dose infiltration in the surgical site for postsurgical analgesia. Bupivicaine is released ...